WO2004093886A1 - Topical formulation of ivermectin for the treatment of dermatological conditions - Google Patents
Topical formulation of ivermectin for the treatment of dermatological conditions Download PDFInfo
- Publication number
- WO2004093886A1 WO2004093886A1 PCT/EP2004/004950 EP2004004950W WO2004093886A1 WO 2004093886 A1 WO2004093886 A1 WO 2004093886A1 EP 2004004950 W EP2004004950 W EP 2004004950W WO 2004093886 A1 WO2004093886 A1 WO 2004093886A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- composition
- ivermectin
- use according
- water
- surfactant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/08—Antiseborrheics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/10—Anti-acne agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
Definitions
- the present invention relates to the use of ivermectin for producing a topical pharmaceutical 5 composition intended for the treatment of rosacea. It also relates to a topical pharmaceutical composition intended for human use, comprising ivermectin.
- Ivermectin is a mixture of two compounds belonging to the avermectin class, 5-0-demethyl-22, 23-
- Ivermectin contains at least 80% of 22,23- dihydroaver ectin B ⁇ a and less than 20% of 22,23-
- ivermectin was presented as a broad-spectrum antiparasitic medicinal product for veterinary use (W.C. CAMPBELL, et al., (1983). Ivermectin: a potent new antiparasitic agent.
- Ivermectin also interacts with other ligand- dependent chloride channels, such as those involving the neuro ediator GABA (gamma-aminobutyric acid) . Ivermectin is more particularly an anthelmintic.
- US patent 6,133,310 discloses the use of ivermectin topically in the form of a prototype of a lotion consisting of a mixture of ivermectin and water, and also mentions the possibility of a prototype of a cream consisting, for its part, of a mixture of ivermectin and an excipient such as propylene glycol or sodium lauryl sulphate, but describes no pharmaceutical composition as such. These mixtures are similar to experimental preparations used in the context of initial results of proof of concept.
- the Applicant has developed a topical pharmaceutical composition intended for the treatment of humans, containing ivermectin.
- the composition according to the invention exhibits very good stability, in particular at different pHs, and good tolerance on the skin.
- it is found that it is particularly suitable for the treatment of dermatological conditions, and more particularly well suited to the treatment of rosacea.
- a subject of the present invention is also the use of ivermectin for producing a topical pharmaceutical composition intended for the treatment of rosacea, topical pharmaceutical compositions intended for human use, comprising ivermectin, and the use of these topical pharmaceutical compositions for the treatment of rosacea.
- the ivermectin according to the invention contains at least 80% of 22, 23-dihydroavermectin B la and less than 20% of 22, 23-dihydroavermectin B ib .
- the pharmaceutical composition which can be used according to the invention is intended for treating the skin and may be in liquid, pasty or solid form, and more particularly in the form of ointments, creams, milks, pomades, powders, impregnated pads, syndets, towelettes, solutions, gels, sprays, foams, suspensions, lotions, sticks, shampoos or washing bases. It may also be in the form of suspensions of microspheres or nanospheres or of lipid or polymeric vesicles or of polymeric patches and of hydrogels for controlled release.
- This composition for topical application may be in anhydrous form, in aqueous form of in the form of an emulsion.
- the pharmaceutical composition according to the invention is in the form of an emulsion of the cream or lotion type, of a gel, or of a solution.
- composition according to the invention is in the form of an emulsion.
- Surfactant-emulsifiers are amphiphilic compounds which possess a hydrophobic component having affinity for oil and a hydrophilic component having affinity for water, thus creating a link between the two phases. Ionic or nonionic emulsifiers therefore stabilize oil/water emulsions by adsorbing to the interface and forming lamellar layers of liquid crystals.
- the emulsifier power of nonionic surfactants is closely linked to the polarity of the molecule. This polarity is defined by the HLB (hydrophilic/lipophilic balance) .
- HLB hydrophilic/lipophilic balance
- Conventional emulsions are generally stabilized by a mixture of surfactants, the HLBs of which can be quite different but the proportion of which in the mixture corresponds to the required HLB of the fatty phase to be emulsified.
- composition according to the invention will contain this type of ingredient.
- composition according to the invention is described as a stable emulsion in that it exhibits good physical and chemical stability over time, even at a temperature above ambient temperature (for example 45- 55°C) , as shown in the examples described hereinafter.
- the ivermectin in the composition according to the invention also, surprisingly, exhibits good chemical stability in the case of pH variation.
- composition according to the invention is advantageously an emulsion which comprises: a) an oily phase comprising fatty substances; b) at least one surfactant-emulsifier; c) ivermectin; d) one or more solvent (s) and/or propenetrating agent (s) for the active agent; e) and water.
- composition according to the invention is an emulsion which comprises: a) an oily phase comprising fatty substances; b) at least one surfactant-emulsifier; c) ivermectin; d) one or more solvent (s) and/or propenetrating agent (s) for the active agent; e) one or more gelling agent (s) ; f) and water.
- the oily phase of the composition according to the invention may comprise, for example, vegetable, mineral, animal or synthetic oils, silicone oils, Guerbet alcohols or other substances, and mixtures thereof.
- paraffin oils of various viscosities such as Primol 352, Marcol 82 or Marcol 152 sold by the company Esso.
- a vegetable oil mention may be made of sweet almond oil, palm oil, soybean oil, sesame oil and sunflower oil.
- an animal oil mention may be made of lanolin, squalene, fish oil and mink oil.
- esters such as cetearyl isononanoate sold in particular under the name Cetiol SN by the company Cognis France, diisopropyl adipate, for instance the product sold under the name Ceraphyl 230 by the company ISF, isopropyl palmitate, for instance the product sold under the name Crodamol IPP by the company Croda, or caprylic capric triglyceride such as Miglyol 812 sold by the company Huls/Lambert Riviere.
- esters such as cetearyl isononanoate sold in particular under the name Cetiol SN by the company Cognis France, diisopropyl adipate, for instance the product sold under the name Ceraphyl 230 by the company ISF, isopropyl palmitate, for instance the product sold under the name Crodamol IPP by the company Croda, or caprylic capric triglyceride such as Miglyol 812 sold by the company Huls/
- silicone oil mention may be made of a dimethicone, such as the product sold under the name Dow Corning 200 fluid, or a cyclomethicone, such as the product sold under the name Dow Corning 244 fluid by the company Dow Corning, or the product sold under the name Mirasil CM5 by the company SACI-CFPA.
- fatty acids such as stearic acid, fatty alcohols such as stearyl alcohol, cetostearyl alcohol and cetyl alcohol, or derivatives thereof, waxes such as beeswax, carnauba wax or candelilla wax, and also gums, in particular silicone gums.
- the ingredients of the oily phase may be chosen in a varied manner by those skilled in the art in order to prepare a composition having the desired properties, for example of consistency or of texture.
- the oily phase of the composition according to the invention preferably comprises a synthetic oil and/or a silicone oil; as synthetic oil, isopropyl palmitate such as the product sold under the name Crodamol IPP by the company Croda or isopropyl myristate such as the product sold under the name Crodamol IPM by the company Croda is preferred; as silicone oil, a di harmonyone is preferred.
- the oily phase of the emulsion according to the invention may be present at a content of between 3 and 50% by weight relative to the total weight of the composition, and preferably between 6 and 20% by weight.
- compositions according to the invention contain surfactant-emulsifiers .
- surfactant-emulsifiers include surfactant-emulsifiers .
- these compounds mention may be made, by way of examples, of the glyceryl/PEG 100 stearate sold under the name Arlacel 165FL by the company UNIQEMA or under the name Simulsol 165 by the company SEPPIC; polyoxyethylenated fatty acid esters such as Arlatone 983 from the company UNIQEMA or the polyoxyethylenated (2) stearyl alcohol sold under the name Brij72 combined with the polyethylenated (21) stearyl alcohol sold under the name Brij721 by the company UNIQEMA; sorbitan esters such as the sorbitan oleate sold under the name Arlacel 80 by the company ICI or sold under the name Crill 4 by the company Croda, the sorbitan sesquioleate sold under the name Arlacel 83 by the company ICI or sold
- composition according to the invention advantageously comprises up to 15% by weight of suitable surfactant-emulsifier, preferably from 2 to 12% by weight, and more particularly from 2 to 6% by weight, relative to the total weight of the composition.
- suitable surfactant-emulsifier preferably from 2 to 12% by weight, and more particularly from 2 to 6% by weight, relative to the total weight of the composition.
- the composition according to the invention comprises from 0.001 to 10% of ivermectin by weight relative to the total weight of the composition.
- the composition according to the invention contains from 0.1 to 5% of ivermectin by weight relative to the total weight of the composition.
- a solvent and/or propenetrating agent for the ivermectin active agent mention will preferably be made of propylene glycol, alcohols such as ethanol, isopropanol, butanol, N- methyl-2-pyrrolidone or DMSO, polysorbate 80, phenoxyethanol, and mixtures thereof.
- the table below illustrates the solubility of ivermectin in various solvents:
- composition of the invention contains from 0.1 to 20%, and preferably from 1 to 10%, of a solvent and/or propenetrating agent for the ivermectin active agent.
- composition according to the invention may also comprise aqueous phase gelling compounds ranging from 0.01 to 5% by weight relative to the total weight of the composition.
- gelling agents which can be used in the composition according to the invention, mention may be made of carboxyvinyl polymers (carbomers) and, by way of nonlimiting examples, of carbomer, Carbopol 981, Carbopol ETD 2020, Carbopol 980, Carbopol Ultrez 10 NF and Pemulen TRl, sold by the company NOVEON.
- cellulose derivatives such as, for example, hydroxypropylmethylcellulose or hydroxyethylcellulose; xanthan gums, aluminium/magnesium silicates such as Veegum K or Veegum Ultra resold by Vanderbilt, guar gums and the like, polyacrylamides such as the mixture polyacrylamide/C13-14 isoparaffin/laureth-7, for instance that sold, for example, by the company SEPPIC under the name Sepigel 305, or the mixture acrylamide, AMPS copolymer dispersion 40%/isohexadecane under the name Simulgel 600PHA, or the family of modified starches such as Structure Solanace resold by National Starch, or mixtures thereof.
- cellulose derivatives such as, for example, hydroxypropylmethylcellulose or hydroxyethylcellulose
- xanthan gums aluminium/magnesium silicates such as Veegum K or Veegum Ultra resold by Vanderbilt,
- composition of the invention preferentially contains from 0.01 to 5%, and preferably from 0.1 to 3%, of gelling agent.
- composition of the invention also contains water ranging from 30 to 95%, and preferably from 60 to 80%, by weight relative to the total weight of the composition.
- the water used in the composition according to the invention will preferably be purified water.
- the pharmaceutical composition according to the invention may also contain inert additives or combinations of these additives, such as flavour enhancers; preserving agents; stabilizers; - humidity regulators; pH regulators; osmotic pressure modifiers; UV-A and UV-B screening agents; and antioxidants .
- inert additives or combinations of these additives such as flavour enhancers; preserving agents; stabilizers; - humidity regulators; pH regulators; osmotic pressure modifiers; UV-A and UV-B screening agents; and antioxidants .
- additives may be present in the composition at from 0.001 to 20% by weight relative to the total weight of the composition.
- composition according to the invention is advantageously an emulsion which comprises: a) 6 to 20% of an oily phase; b) 2 to 12% of a surfactant-emulsifier; c) 0.1 to 5% of ivermectin; d) 0.1 to 20% of solvent; e) 0.01 to 5% of gelling agents; f) and water.
- the pH will preferably be between 6.0 and
- Verification of the natural pH of the mixture and possible correction with a solution of a neutralising agent, and also the incorporation of the optional additives, may be carried out, according to their chemical nature, during one of the steps of the method of preparation, described above.
- compositions which can be used according to the present invention are illustrated in Examples 1 to 6.
- the subject of the present invention is also a topical composition intended for human use, characterized in that it is an emulsion comprising: a) an oily phase comprising fatty substances; b) at least one surfactant-emulsifier; c) ivermectin; d) one or more solvent (s) and/or propenetrating agent (s) for the active agent; e) and water.
- this composition may comprise: a) an oily phase comprising fatty substances; b) at least one surfactant-emulsifier; c) ivermectin; d) one or more solvent (s) and/or propenetrating agent (s) for the active agent; e) one or more gelling agent (s) ; f) and water.
- the composition comprises: a) 6 to 20% of an oily phase; b) 2 to 12% of a surfactant-emulsifier; c) 0.1 to 5% of ivermectin; d) 0.1 to 20% of solvent; e) 0.01 to 5% of gelling agents; f) and water.
- compositions 1 to 6 illustrate the compositions according to the invention.
- a subject of the invention is also the use of the composition according to the invention, for producing a pharmaceutical preparation intended to treat dermatological conditions.
- the use of ivermectin for producing a topical pharmaceutical composition for human use according to the invention is particularly intended for the treatment of rosacea, of common acne, of seborrhoeic dermatitis, of perioral dermatitis, of acneform rashes, of transient acantholytic dermatosis, and of acne necrotica miliaris.
- the use of ivermectin for producing a topical pharmaceutical composition for human use according to the invention is more particularly intended for the treatment of rosacea.
- Various formulations of compositions comprising ivermectin, and also results for stability and tolerance obtained with compositions according to the invention will now be given by way of illustration which is no way limiting in nature.
- aqueous phase In a first suitable container, weigh the aqueous phase, mix at 700 rpm and heat to 65°-70°C.
- Examples 5 and 6 are realized according to the following procedure: - Aqueous phase In a first beaker, disperse the acrylate/clO-
- Example 5 A randomized single-blind intra-individual study was carried out on 15 individuals with skin tending to be affected by rosacea.
- the composition of Example 5 was tested in comparison with a gel and with an emulsion having compositions different from the compositions according to the invention.
- the following clinical tolerance parameters were evaluated: stinging sensation, burning, dry skin, tightness or itching.
- the following cosmetic acceptability parameters were evaluated: creaminess, texture, lack of a sensation of greasy and sticky skin, nourishing nature, feeling of comfort and of softness to the touch.
- composition according to the invention was judged to be well tolerated by the individuals, to the same extent as the two other compositions.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Dispersion Chemistry (AREA)
- Molecular Biology (AREA)
- Toxicology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Saccharide Compounds (AREA)
Abstract
Description
Claims
Priority Applications (27)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2004231323A AU2004231323C1 (en) | 2003-04-24 | 2004-04-22 | Topical formulation of ivermectin for the treatment of dermatological conditions |
PL04728811T PL1620113T3 (en) | 2003-04-24 | 2004-04-22 | Topical formulation of ivermectin for the treatment of dermatological conditions |
KR1020057019402A KR101187231B1 (en) | 2003-04-24 | 2004-04-22 | Topical formulation of ivermectin for the treatment of dermatological conditions |
SI200431722T SI1620113T1 (en) | 2003-04-24 | 2004-04-22 | Topical formulation of ivermectin for the treatment of dermatological conditions |
MXPA05011208A MXPA05011208A (en) | 2003-04-24 | 2004-04-22 | Topical formulation of ivermectin for the treatment of dermatological conditions. |
AT04728811T ATE516037T1 (en) | 2003-04-24 | 2004-04-22 | TOPICAL FORMULATION OF IVERMECTIN FOR THE TREATMENT OF DERMATOLOGICAL DISEASES |
KR1020127013727A KR101291824B1 (en) | 2003-04-24 | 2004-04-22 | Topical formulation of ivermectin for the treatment of dermatological conditions |
JP2006505405A JP5711867B2 (en) | 2003-04-24 | 2004-04-22 | Use of ivermectin for the treatment of dermatological diseases |
BRPI0410503A BRPI0410503B8 (en) | 2003-04-24 | 2004-04-22 | topical composition and use of composition |
DK04728811.3T DK1620113T3 (en) | 2003-04-24 | 2004-04-22 | Topical formulation of ivermectin for the treatment of dermatological disorders |
CA2522579A CA2522579C (en) | 2003-04-24 | 2004-04-22 | Topical formulation of ivermectin for the treatment of dermatological conditions |
EP04728811A EP1620113B1 (en) | 2003-04-24 | 2004-04-22 | Topical formulation of ivermectin for the treatment of dermatological conditions |
US11/255,910 US7550440B2 (en) | 2003-04-24 | 2005-10-24 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
US12/468,287 US8080530B2 (en) | 2003-04-24 | 2009-05-19 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
US12/483,604 US8093219B2 (en) | 2003-04-24 | 2009-06-12 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
US13/310,633 US8415311B2 (en) | 2003-04-24 | 2011-12-02 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
US13/529,971 US8470788B2 (en) | 2003-04-24 | 2012-06-21 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
US13/851,816 US8598129B2 (en) | 2003-04-24 | 2013-03-27 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
US14/063,897 US8815816B2 (en) | 2003-04-24 | 2013-10-25 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
US14/337,966 US20140336139A1 (en) | 2003-04-24 | 2014-07-22 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
US14/792,250 US20150306027A1 (en) | 2003-04-24 | 2015-07-06 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
US14/792,201 US20150306124A1 (en) | 2003-04-24 | 2015-07-06 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
LTPA2015033C LTC1620113I2 (en) | 2003-04-24 | 2015-09-24 | Ivermectin topical composition for the treatment of dermatological diseases |
LU92915C LU92915I2 (en) | 2003-04-24 | 2015-12-17 | IVERMECTIN FOR USE IN THE TREATMENT OF ROSACEAE |
CY2016031C CY2016031I1 (en) | 2003-04-24 | 2016-09-09 | TOPICAL PHARMACEUTICAL FORM OF IVERMECTIN FOR THE TREATMENT OF DERMATOLOGICAL CONDITIONS |
US15/625,362 US11033565B2 (en) | 2003-04-24 | 2017-06-16 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
US15/625,239 US20170281663A1 (en) | 2003-04-24 | 2017-06-16 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR03/05048 | 2003-04-24 | ||
FR0305048A FR2854074B1 (en) | 2003-04-24 | 2003-04-24 | USE OF IVERMECTIN FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS |
US46899403P | 2003-05-09 | 2003-05-09 | |
US60/468,994 | 2003-05-09 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/255,910 Continuation US7550440B2 (en) | 2003-04-24 | 2005-10-24 | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2004093886A1 true WO2004093886A1 (en) | 2004-11-04 |
Family
ID=33312271
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/004950 WO2004093886A1 (en) | 2003-04-24 | 2004-04-22 | Topical formulation of ivermectin for the treatment of dermatological conditions |
Country Status (15)
Country | Link |
---|---|
US (6) | US7550440B2 (en) |
EP (1) | EP1620113B1 (en) |
JP (2) | JP5711867B2 (en) |
KR (1) | KR101187231B1 (en) |
AU (1) | AU2004231323C1 (en) |
BR (1) | BRPI0410503B8 (en) |
CA (1) | CA2522579C (en) |
CY (2) | CY1111797T1 (en) |
HU (1) | HUS1500048I1 (en) |
LT (1) | LTC1620113I2 (en) |
LU (1) | LU92915I2 (en) |
MX (1) | MXPA05011208A (en) |
PL (2) | PL1620113T3 (en) |
RU (1) | RU2350333C3 (en) |
WO (1) | WO2004093886A1 (en) |
Cited By (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005089806A1 (en) * | 2004-03-18 | 2005-09-29 | Galderma S.A. | Cream-gel containing ivermectin |
WO2006131651A2 (en) * | 2005-06-10 | 2006-12-14 | Galderma S.A | Avermectin and hydrocortisone-based composition, in particular for roracea treatment |
WO2006131653A1 (en) * | 2005-06-10 | 2006-12-14 | Galderma S.A. | Composition based on an avermectine and metronidazole in particular for treating rosacea |
WO2006131652A1 (en) * | 2005-06-10 | 2006-12-14 | Galderma S.A. | Composition based on an avermectine and benzoyl peroxide in particular for treating rosacea |
FR2894823A1 (en) * | 2005-12-20 | 2007-06-22 | Galderma Sa | REVERSE EMULSION TYPE COMPOSITION COMPRISING IVERMECTIN AND ITS USES IN COSMETICS AND DERMATOLOGY |
WO2007119028A2 (en) * | 2006-04-19 | 2007-10-25 | Galderma S.A. | Composition including at least one aqueous phase and at least one fatty phase including ivermectin |
WO2008043973A1 (en) * | 2006-10-12 | 2008-04-17 | Galderma S.A. | Dermatological composition containing avermictin nanocapsules, method for preparing the same and uses thereof |
WO2008043974A2 (en) * | 2006-10-12 | 2008-04-17 | Galderma S.A. | Two-compartment skincare products comprising ivermectin, and uses thereof |
WO2010051348A1 (en) | 2008-10-29 | 2010-05-06 | Topaz Pharmaceuticals Inc. | Preservative system for emulsion-based therapeutic topical formulations |
EP2653160A1 (en) * | 2006-10-12 | 2013-10-23 | Topaz Pharmaceuticals Inc. | Topical avermectin formulations and methods for elimination and prophylaxis of body lice |
WO2014049298A1 (en) * | 2012-09-28 | 2014-04-03 | Galderma Research & Development | Combination of laropiprant and ivermectin for the treatment of rosacea |
US8858967B2 (en) | 2004-03-18 | 2014-10-14 | Galderma S.A. | Dermatological cream-gels containing avermectin compounds |
WO2015006305A1 (en) * | 2013-07-08 | 2015-01-15 | Galderma S.A. | Treatment of inflammatory lesions of rosacea with ivermectin |
US20150045315A1 (en) * | 2007-01-03 | 2015-02-12 | Galderma S. A. | Method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by insect stings or noxious weeds or plants using avermectin compound |
WO2015079016A1 (en) | 2013-11-29 | 2015-06-04 | Galderma Sa | Compound of the avermectin family or of the milbemycin family for the treatment and/or prevention of atopic dermatitis |
CN104706584A (en) * | 2013-12-16 | 2015-06-17 | 天津迈迪瑞康生物医药科技有限公司 | Ivermectin fat emulsion concentrated solution, preparation method and application thereof |
US20150223449A1 (en) * | 2012-08-27 | 2015-08-13 | Maruwa Biochemical Co., Ltd. | Chemical Agent For Controlling Soil Nematode Which Comprises Macrolide-Type Compound |
WO2016022066A1 (en) * | 2014-08-04 | 2016-02-11 | Jerry Tan Eye Surgery Pte Ltd | Pharmaceutical compositions for demodex related blepharitis and eyelid crusting |
WO2016042117A1 (en) * | 2014-09-18 | 2016-03-24 | Galderma Sa | Composition comprising a compound from the family of avermectins and doxycycline for the treatment of rosacea |
WO2016096795A1 (en) * | 2014-12-15 | 2016-06-23 | Galderma Sa | Compound of the avermectin family for treating and/or preventing inflammatory dermatoses |
WO2016096797A1 (en) | 2014-12-15 | 2016-06-23 | Galderma Sa | Compound of the avermectin family in combination with an other active compound for treating and/or preventing inflammatory dermatoses |
WO2017064206A1 (en) | 2015-10-13 | 2017-04-20 | Galderma Sa | A process for preparing a composition comprising a high concentration of one or more avermectins |
WO2017064205A1 (en) | 2015-10-13 | 2017-04-20 | Galderma Sa | A process for preparing a stable emulsion comprising one or more avermectins |
US9782425B2 (en) | 2013-07-08 | 2017-10-10 | Galderma S.A. | Treatment of papulopustular rosacea with ivermectin |
WO2018024888A1 (en) | 2016-08-04 | 2018-02-08 | Nestlé Skin Health Sa | Compositions and the use thereof for treating or preventing rosacea |
WO2018083196A1 (en) | 2016-11-03 | 2018-05-11 | Nestlé Skin Health Sa | Compositions comprising a compound of the avermectin family for the treatment and/or prevention of hand eczema |
US10052340B2 (en) | 2012-10-19 | 2018-08-21 | Xiamen University | Use of ivermectin and derivatives thereof |
EP2419082B1 (en) * | 2008-12-23 | 2020-01-22 | Galderma S.A. | Topical pharmaceutical composition containing a water-sensitive active principle |
WO2021035086A1 (en) * | 2019-08-21 | 2021-02-25 | Timber Pharmaceuticals, Inc. | Solvent delivery system for topical delivery of active agents |
US11033565B2 (en) | 2003-04-24 | 2021-06-15 | Galderma Holding SA | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
US11197847B2 (en) | 2017-12-15 | 2021-12-14 | Tarsus Pharmaceuticals, Inc. | Isoxazoline parasiticide formulations and methods for treating blepharitis |
KR20220052473A (en) | 2020-10-21 | 2022-04-28 | 순천향대학교 산학협력단 | MicroRNA-31-5p for diagnosing rosacea and use thereof |
KR20220052474A (en) | 2020-10-21 | 2022-04-28 | 순천향대학교 산학협력단 | MicroRNA-21-3p for diagnosing rosacea and use thereof |
RU2792693C2 (en) * | 2013-11-29 | 2023-03-23 | Галдерма Са | Avermectin or milbemycin family compound for treatment and/or prevention of adopic dermatitis |
Families Citing this family (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0410503B8 (en) * | 2003-04-24 | 2021-05-25 | Galderma Sa | topical composition and use of composition |
MXPA05012791A (en) * | 2003-05-25 | 2006-02-22 | Wang Yuwan | Dimeticone-containing sustained formulation. |
FR2883181B1 (en) | 2005-03-17 | 2007-05-18 | Galderma Sa | COMPOSITION BASED ON AVERMECTIN AND AZELAIC ACID, IN PARTICULAR FOR THE TREATMENT OF ROSACEA |
FR2906468B1 (en) * | 2006-09-28 | 2012-09-21 | Galderma Sa | USE OF COMPOUNDS OF THE AVERMECTIN FAMILY FOR THE TREATMENT OF DERMATOLOGICAL DISORDERS |
DE102007056424A1 (en) * | 2007-11-23 | 2009-05-28 | Neopharmacie Gmbh | Pharmaceutical composition containing an oil / water emulsion |
US8642665B2 (en) | 2011-12-16 | 2014-02-04 | Conopco, Inc. | Environmentally friendly, low whitening compositions |
FR3003761B1 (en) * | 2013-03-29 | 2016-01-01 | Galderma Sa | USE OF MACROCYCLIC LACTONE FOR THE TREATMENT OF INFECTION WITH PAPILLOMAVIRUS |
US11813284B2 (en) | 2013-08-08 | 2023-11-14 | Novan, Inc. | Topical compositions and methods of using the same |
US10322082B2 (en) | 2014-07-11 | 2019-06-18 | Novan, Inc. | Topical antiviral compositions and methods of using the same |
US11160780B2 (en) * | 2016-09-30 | 2021-11-02 | Aurobindo Pharma Ltd. | Pharmaceutical composition of ivermectin and process for preparation thereof |
EP3326608A1 (en) | 2016-11-24 | 2018-05-30 | Nestlé Skin Health SA | Composition comprising avermectin compounds without solid fatty substances |
EP3326609A1 (en) | 2016-11-24 | 2018-05-30 | Nestlé Skin Health SA | Composition comprising avermectin compounds without gelling agents |
EP3326614A1 (en) | 2016-11-24 | 2018-05-30 | Nestlé Skin Health SA | Composition comprising avermectin compounds without solvents and propenetrating agents of avermectin compounds |
BR112019026073B1 (en) * | 2017-06-12 | 2021-11-03 | Lakewood Amedex, Inc | NU-3 GEL FORMULATIONS AND USES THEREOF |
WO2020064843A1 (en) * | 2018-09-28 | 2020-04-02 | Galderma Research & Development | Pharmaceutical composition in the form of a water-in-oil emulsion (w/o) and its uses |
US11312922B2 (en) | 2019-04-12 | 2022-04-26 | Ecolab Usa Inc. | Antimicrobial multi-purpose cleaner comprising a sulfonic acid-containing surfactant and methods of making and using the same |
US11291679B1 (en) * | 2021-03-22 | 2022-04-05 | Mountain Valley Md Inc. | Injectable, infusable, instillable ivermectin adjuvant for cancer therapies |
EP4062907A1 (en) | 2021-03-23 | 2022-09-28 | Substipharm | Formulation for oral administration of ivermectin and uses thereof |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001028555A1 (en) * | 1999-10-18 | 2001-04-26 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
US20020035076A1 (en) * | 2000-06-29 | 2002-03-21 | Parks L. Dean | Method of treating dermatoses using avermectin compound |
US20020061855A1 (en) * | 2000-06-29 | 2002-05-23 | Parks L. Dean | Method of treating acne vulgaris using avermectin compound |
WO2003066009A1 (en) * | 2002-02-08 | 2003-08-14 | Merck & Co., Inc. | Topical ivermectin composition |
WO2003075656A2 (en) * | 2002-03-04 | 2003-09-18 | Divergence, Inc. | Nematicidal fatty acid and fatty acid ester related compounds |
Family Cites Families (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5332577A (en) | 1988-12-27 | 1994-07-26 | Dermamed | Transdermal administration to humans and animals |
US5952371A (en) * | 1996-10-16 | 1999-09-14 | Merck & Co., Inc. | Triterpene derivatives with immunosuppressant activity |
US5952372A (en) * | 1998-09-17 | 1999-09-14 | Mcdaniel; William Robert | Method for treating rosacea using oral or topical ivermectin |
US6310968B1 (en) * | 1998-11-24 | 2001-10-30 | Picker International, Inc. | Source-assisted attenuation correction for emission computed tomography |
IL144561A0 (en) * | 1999-01-25 | 2002-05-23 | Optime Therapeutics Inc | Liposome compositions and methods for treating pests utilizing the same |
US6133310A (en) * | 1999-08-26 | 2000-10-17 | Parks; L. Dean | Method of treatment of rosacea |
US6319945B1 (en) | 2000-06-29 | 2001-11-20 | L. Dean Parks | Method of treatment of seborrheic dermatitis |
DE10063946A1 (en) * | 2000-12-20 | 2002-07-04 | Basf Ag | Use of light stabilizer combinations which contain 2,2'-p-phenylene-bis (3,1-benzoxazin-4-one) as an essential constituent as a photostable UV filter in cosmetic and pharmaceutical preparations |
BRPI0410503B8 (en) * | 2003-04-24 | 2021-05-25 | Galderma Sa | topical composition and use of composition |
FR2867684B1 (en) | 2004-03-18 | 2006-05-05 | Galderma Sa | CREAM GEL CONTAINING IVERMECTIN |
DE602005020912D1 (en) | 2004-03-18 | 2010-06-10 | Galderma Sa | IVERMECTIN CONTAINING CREAM |
-
2004
- 2004-04-22 BR BRPI0410503A patent/BRPI0410503B8/en active IP Right Grant
- 2004-04-22 PL PL04728811T patent/PL1620113T3/en unknown
- 2004-04-22 KR KR1020057019402A patent/KR101187231B1/en active IP Right Grant
- 2004-04-22 CA CA2522579A patent/CA2522579C/en not_active Expired - Fee Related
- 2004-04-22 AU AU2004231323A patent/AU2004231323C1/en active Active
- 2004-04-22 EP EP04728811A patent/EP1620113B1/en not_active Expired - Lifetime
- 2004-04-22 RU RU2005136438A patent/RU2350333C3/en active Protection Beyond IP Right Term
- 2004-04-22 JP JP2006505405A patent/JP5711867B2/en not_active Expired - Lifetime
- 2004-04-22 MX MXPA05011208A patent/MXPA05011208A/en active IP Right Grant
- 2004-04-22 PL PL378932A patent/PL378932A1/en not_active Application Discontinuation
- 2004-04-22 WO PCT/EP2004/004950 patent/WO2004093886A1/en active Application Filing
-
2005
- 2005-10-24 US US11/255,910 patent/US7550440B2/en not_active Expired - Lifetime
-
2009
- 2009-05-19 US US12/468,287 patent/US8080530B2/en not_active Expired - Lifetime
- 2009-06-12 US US12/483,604 patent/US8093219B2/en not_active Expired - Lifetime
-
2011
- 2011-09-07 CY CY20111100856T patent/CY1111797T1/en unknown
- 2011-12-02 US US13/310,633 patent/US8415311B2/en not_active Expired - Lifetime
-
2012
- 2012-03-22 JP JP2012065724A patent/JP5538461B2/en not_active Expired - Lifetime
- 2012-06-21 US US13/529,971 patent/US8470788B2/en not_active Expired - Lifetime
-
2013
- 2013-03-27 US US13/851,816 patent/US8598129B2/en not_active Expired - Lifetime
-
2015
- 2015-09-22 HU HUS1500048C patent/HUS1500048I1/en unknown
- 2015-09-24 LT LTPA2015033C patent/LTC1620113I2/en unknown
- 2015-12-17 LU LU92915C patent/LU92915I2/en unknown
-
2016
- 2016-09-09 CY CY2016031C patent/CY2016031I1/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001028555A1 (en) * | 1999-10-18 | 2001-04-26 | Lipocine, Inc. | Emulsion compositions for polyfunctional active ingredients |
US20020035076A1 (en) * | 2000-06-29 | 2002-03-21 | Parks L. Dean | Method of treating dermatoses using avermectin compound |
US20020061855A1 (en) * | 2000-06-29 | 2002-05-23 | Parks L. Dean | Method of treating acne vulgaris using avermectin compound |
WO2003066009A1 (en) * | 2002-02-08 | 2003-08-14 | Merck & Co., Inc. | Topical ivermectin composition |
WO2003075656A2 (en) * | 2002-03-04 | 2003-09-18 | Divergence, Inc. | Nematicidal fatty acid and fatty acid ester related compounds |
Non-Patent Citations (1)
Title |
---|
"Cetaphil cleansers and moisturizers", 2004, XP002287576, Retrieved from the Internet <URL:http://www.cetaphil.com/product_information/moisturizers.cfm> [retrieved on 20040708] * |
Cited By (89)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11033565B2 (en) | 2003-04-24 | 2021-06-15 | Galderma Holding SA | Topical application of ivermectin for the treatment of dermatological conditions/afflictions |
JP2007529465A (en) * | 2004-03-18 | 2007-10-25 | ガルデルマ・ソシエテ・アノニム | Cream-gel containing ivermectin |
US8858967B2 (en) | 2004-03-18 | 2014-10-14 | Galderma S.A. | Dermatological cream-gels containing avermectin compounds |
WO2005089806A1 (en) * | 2004-03-18 | 2005-09-29 | Galderma S.A. | Cream-gel containing ivermectin |
AU2005224038B2 (en) * | 2004-03-18 | 2011-06-23 | Galderma S.A. | Cream-gel containing ivermectin |
FR2886850A1 (en) * | 2005-06-10 | 2006-12-15 | Galderma Sa | COMPOSITION BASED ON AVERMECTIN AND BENZOYL PEROXIDE, IN PARTICULAR FOR THE TREATMENT OF ROSACEA |
FR2886852A1 (en) * | 2005-06-10 | 2006-12-15 | Galderma Sa | COMPOSITION BASED ON AVERMECTIN AND HYDROCORTISONE, IN PARTICULAR FOR THE TREATMENT OF ROSACEA |
WO2006131651A3 (en) * | 2005-06-10 | 2007-09-13 | Galderma Sa | Avermectin and hydrocortisone-based composition, in particular for roracea treatment |
FR2886851A1 (en) * | 2005-06-10 | 2006-12-15 | Galderma Sa | COMPOSITION BASED ON AVERMECTIN AND METRONIDAZOLE, IN PARTICULAR FOR THE TREATMENT OF ROSACEA |
EP2457568A1 (en) * | 2005-06-10 | 2012-05-30 | Galderma S.A. | Composition comprising an avermectine and metronidazole in particular for treating rosacea |
US20110052515A1 (en) * | 2005-06-10 | 2011-03-03 | Galderma S.A. | Avermectin/benzoyl peroxide compositions for treating affliction of the skin, e.g., rosacea |
US20110003763A1 (en) * | 2005-06-10 | 2011-01-06 | Galderma S.A. | Avermectin/benzoyl peroxide compositions for treating afflictions of the skin, e.g., rosacea |
WO2006131652A1 (en) * | 2005-06-10 | 2006-12-14 | Galderma S.A. | Composition based on an avermectine and benzoyl peroxide in particular for treating rosacea |
WO2006131653A1 (en) * | 2005-06-10 | 2006-12-14 | Galderma S.A. | Composition based on an avermectine and metronidazole in particular for treating rosacea |
WO2006131651A2 (en) * | 2005-06-10 | 2006-12-14 | Galderma S.A | Avermectin and hydrocortisone-based composition, in particular for roracea treatment |
FR2894823A1 (en) * | 2005-12-20 | 2007-06-22 | Galderma Sa | REVERSE EMULSION TYPE COMPOSITION COMPRISING IVERMECTIN AND ITS USES IN COSMETICS AND DERMATOLOGY |
WO2007071876A1 (en) | 2005-12-20 | 2007-06-28 | Galderma S.A. | Composition of inverse emulsion type comprising ivermectin, and uses thereof in cosmetics and dermatology |
US8287891B2 (en) | 2005-12-20 | 2012-10-16 | Galderma S.A. | Inverse emulsions comprising avermectins and cosmetic/dermatological applications thereof |
FR2900052A1 (en) * | 2006-04-19 | 2007-10-26 | Galderma Sa | COMPOSITION COMPRISING AT LEAST ONE AQUEOUS PHASE AND AT LEAST ONE FATTY PHASE COMPRISING IVERMECTIN |
JP2009534362A (en) * | 2006-04-19 | 2009-09-24 | ガルデルマ・ソシエテ・アノニム | A composition comprising at least one fatty phase and at least one aqueous phase comprising ivermectin |
US8362069B2 (en) | 2006-04-19 | 2013-01-29 | Galderma S.A. | Compositions comprising at least one aqueous phase and at least one fatty phase which comprises avermectin compounds |
US9592249B2 (en) | 2006-04-19 | 2017-03-14 | Galderma S.A. | Compositions comprising at least one aqueous phase and at least one fatty phase which comprises avermectin compounds |
WO2007119028A3 (en) * | 2006-04-19 | 2008-04-03 | Galderma Sa | Composition including at least one aqueous phase and at least one fatty phase including ivermectin |
EP2374449A3 (en) * | 2006-04-19 | 2012-02-29 | Galderma S.A. | Composition including at least one aqueous phase and at least one oil phase including ivermectin |
WO2007119028A2 (en) * | 2006-04-19 | 2007-10-25 | Galderma S.A. | Composition including at least one aqueous phase and at least one fatty phase including ivermectin |
EP2374449A2 (en) * | 2006-04-19 | 2011-10-12 | Galderma S.A. | Composition including at least one aqueous phase and at least one oil phase including ivermectin |
US8491928B2 (en) | 2006-10-12 | 2013-07-23 | Galderma S.A. | Dermatological compositions comprising avermectin nanocapsules |
FR2907013A1 (en) * | 2006-10-12 | 2008-04-18 | Galderma Sa | CUTANE CARE PRODUCTS WITH DOUBLE COMPARTMENT COMPRISING IVERMECTIN AND USES THEREOF |
US11229207B2 (en) | 2006-10-12 | 2022-01-25 | Arbor Pharmaceuticals, Llc | Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment resistant strains of head lice |
FR2907012A1 (en) * | 2006-10-12 | 2008-04-18 | Galderma Sa | DERMATOLOGICAL COMPOSITION COMPRISING AVERMECTIN NANOCAPSULES, PROCESS FOR PREPARING THE SAME AND USE THEREOF |
US8309121B2 (en) | 2006-10-12 | 2012-11-13 | Galderma S.A. | Dermatological compositions comprising avermectin nanocapsules |
WO2008043974A3 (en) * | 2006-10-12 | 2008-11-13 | Galderma Sa | Two-compartment skincare products comprising ivermectin, and uses thereof |
WO2008043974A2 (en) * | 2006-10-12 | 2008-04-17 | Galderma S.A. | Two-compartment skincare products comprising ivermectin, and uses thereof |
WO2008043973A1 (en) * | 2006-10-12 | 2008-04-17 | Galderma S.A. | Dermatological composition containing avermictin nanocapsules, method for preparing the same and uses thereof |
EP2653160A1 (en) * | 2006-10-12 | 2013-10-23 | Topaz Pharmaceuticals Inc. | Topical avermectin formulations and methods for elimination and prophylaxis of body lice |
US8927595B2 (en) | 2006-10-12 | 2015-01-06 | Sanofi-Topaz, Inc. | Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment resistant strains of head lice |
EP2388009A1 (en) | 2006-10-12 | 2011-11-23 | Galderma S.A. | Dermatological composition containing avermictin nanocapsules, method for preparing the same and uses thereof |
US8791153B2 (en) * | 2006-10-12 | 2014-07-29 | Sanofi-Topaz, Inc. | Topical avermectin formulations and methods for elimination and prophylaxis of susceptible and treatment-resistant strains of head lice |
US8815938B2 (en) | 2006-10-12 | 2014-08-26 | Galderma S.A. | Double compartment skincare products comprising avermectin/milbemycin compounds |
US9662346B2 (en) * | 2007-01-03 | 2017-05-30 | Galderma S.A. | Method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by insect stings or noxious weeds or plants using avermectin compound |
US20150045315A1 (en) * | 2007-01-03 | 2015-02-12 | Galderma S. A. | Method of treating hyperesthesia, paresthesia, dolor, and pruritus caused by insect stings or noxious weeds or plants using avermectin compound |
EP2348832A4 (en) * | 2008-10-29 | 2013-09-11 | Topaz Pharmaceuticals Inc | Preservative system for emulsion-based therapeutic topical formulations |
WO2010051348A1 (en) | 2008-10-29 | 2010-05-06 | Topaz Pharmaceuticals Inc. | Preservative system for emulsion-based therapeutic topical formulations |
EP2348832A1 (en) * | 2008-10-29 | 2011-08-03 | Topaz Pharmaceuticals Inc. | Preservative system for emulsion-based therapeutic topical formulations |
EP2348832B1 (en) | 2008-10-29 | 2019-01-16 | Arbor Pharmaceuticals, LLC | Preservative system for emulsion-based therapeutic topical formulations |
AU2009308922B2 (en) * | 2008-10-29 | 2016-04-14 | Topaz Pharmaceuticals Inc. | Preservative system for emulsion-based therapeutic topical formulations |
EP2419082B1 (en) * | 2008-12-23 | 2020-01-22 | Galderma S.A. | Topical pharmaceutical composition containing a water-sensitive active principle |
US20150223449A1 (en) * | 2012-08-27 | 2015-08-13 | Maruwa Biochemical Co., Ltd. | Chemical Agent For Controlling Soil Nematode Which Comprises Macrolide-Type Compound |
WO2014049298A1 (en) * | 2012-09-28 | 2014-04-03 | Galderma Research & Development | Combination of laropiprant and ivermectin for the treatment of rosacea |
US10052340B2 (en) | 2012-10-19 | 2018-08-21 | Xiamen University | Use of ivermectin and derivatives thereof |
FR3000397A1 (en) * | 2012-12-31 | 2014-07-04 | Galderma Res & Dev | COMBINATION OF LAROPIPRANT AND IVERMECTIN FOR THE TREATMENT OF ROSACEA |
US9233117B2 (en) | 2013-07-08 | 2016-01-12 | Galderma S. A. | Treatment of inflammatory lesions of rosacea with ivermectin |
US10206939B2 (en) | 2013-07-08 | 2019-02-19 | Galderma S.A. | Treatment of papulopustular rosacea with ivermectin |
US9233118B2 (en) | 2013-07-08 | 2016-01-12 | Galderma S.A. | Treatment of papulopustular rosacea with ivermectin |
KR20160061310A (en) * | 2013-07-08 | 2016-05-31 | 갈데르마 소시에떼아노님 | Treatment of Inflammatory Lesions of Rosacea with Ivermectin |
KR20160061311A (en) * | 2013-07-08 | 2016-05-31 | 갈데르마 소시에떼아노님 | Treatment of papulopustular rosacea with ivermectin |
US9089587B2 (en) | 2013-07-08 | 2015-07-28 | Galderma S.A. | Treatment of papulopustular rosacea with ivermectin |
JP2018184437A (en) * | 2013-07-08 | 2018-11-22 | ガルデルマ・ソシエテ・アノニム | Treatment of papulopustular rosacea with ivermectin |
WO2015006319A1 (en) * | 2013-07-08 | 2015-01-15 | Galderma S.A. | Treatment of papulopustular rosacea with ivermectin |
WO2015006305A1 (en) * | 2013-07-08 | 2015-01-15 | Galderma S.A. | Treatment of inflammatory lesions of rosacea with ivermectin |
AU2014287422B2 (en) * | 2013-07-08 | 2017-04-13 | Galderma S.A. | Treatment of papulopustular rosacea with ivermectin |
KR101864799B1 (en) * | 2013-07-08 | 2018-06-05 | 갈데르마 소시에떼아노님 | Treatment of papulopustular rosacea with ivermectin |
KR101863085B1 (en) | 2013-07-08 | 2018-06-01 | 갈데르마 소시에떼아노님 | Treatment of Inflammatory Lesions of Rosacea with Ivermectin |
AU2014287408B2 (en) * | 2013-07-08 | 2017-05-04 | Galderma Holding SA | Treatment of inflammatory lesions of rosacea with ivermectin |
US9782425B2 (en) | 2013-07-08 | 2017-10-10 | Galderma S.A. | Treatment of papulopustular rosacea with ivermectin |
WO2015079016A1 (en) | 2013-11-29 | 2015-06-04 | Galderma Sa | Compound of the avermectin family or of the milbemycin family for the treatment and/or prevention of atopic dermatitis |
US10398720B2 (en) | 2013-11-29 | 2019-09-03 | Galderma Sa | Compound of the avermectin family or of the milbemycin family for the treatment and/or prevention of atopic dermatitis |
RU2792693C2 (en) * | 2013-11-29 | 2023-03-23 | Галдерма Са | Avermectin or milbemycin family compound for treatment and/or prevention of adopic dermatitis |
CN105916511A (en) * | 2013-11-29 | 2016-08-31 | 盖尔德玛公司 | Compound of the avermectin family or of the milbemycin family for the treatment and/or prevention of atopic dermatitis |
RU2669942C1 (en) * | 2013-11-29 | 2018-10-17 | Галдерма Са | Compound of avermectin family or of milbemycin family for treatment and/or prevention of atopic dermatitis |
CN104706584A (en) * | 2013-12-16 | 2015-06-17 | 天津迈迪瑞康生物医药科技有限公司 | Ivermectin fat emulsion concentrated solution, preparation method and application thereof |
WO2016022066A1 (en) * | 2014-08-04 | 2016-02-11 | Jerry Tan Eye Surgery Pte Ltd | Pharmaceutical compositions for demodex related blepharitis and eyelid crusting |
US10463643B2 (en) | 2014-09-18 | 2019-11-05 | Galderma Sa | Composition comprising a compound from the family of avermectins and doxycycline for the treatment of rosacea |
FR3026010A1 (en) * | 2014-09-18 | 2016-03-25 | Galderma Sa | COMPOSITIONS COMPRISING A COMPOUND OF THE AVERMECTIN FAMILY AND DOXYCYCLINE FOR THE TREATMENT OF ROSACEA |
WO2016042117A1 (en) * | 2014-09-18 | 2016-03-24 | Galderma Sa | Composition comprising a compound from the family of avermectins and doxycycline for the treatment of rosacea |
WO2016096797A1 (en) | 2014-12-15 | 2016-06-23 | Galderma Sa | Compound of the avermectin family in combination with an other active compound for treating and/or preventing inflammatory dermatoses |
WO2016096795A1 (en) * | 2014-12-15 | 2016-06-23 | Galderma Sa | Compound of the avermectin family for treating and/or preventing inflammatory dermatoses |
WO2017064205A1 (en) | 2015-10-13 | 2017-04-20 | Galderma Sa | A process for preparing a stable emulsion comprising one or more avermectins |
US10849854B2 (en) | 2015-10-13 | 2020-12-01 | Galderma S.A. | Process for preparing a composition comprising a high concentration of one or more avermectins |
WO2017064206A1 (en) | 2015-10-13 | 2017-04-20 | Galderma Sa | A process for preparing a composition comprising a high concentration of one or more avermectins |
WO2018024888A1 (en) | 2016-08-04 | 2018-02-08 | Nestlé Skin Health Sa | Compositions and the use thereof for treating or preventing rosacea |
WO2018083196A1 (en) | 2016-11-03 | 2018-05-11 | Nestlé Skin Health Sa | Compositions comprising a compound of the avermectin family for the treatment and/or prevention of hand eczema |
US11197847B2 (en) | 2017-12-15 | 2021-12-14 | Tarsus Pharmaceuticals, Inc. | Isoxazoline parasiticide formulations and methods for treating blepharitis |
US11690826B2 (en) | 2017-12-15 | 2023-07-04 | Tarsus Pharmaceuticals, Inc. | Methods for treating demodex blepharitis using lotilaner formulations |
US11690827B2 (en) | 2017-12-15 | 2023-07-04 | Tarsus Pharmaceuticals, Inc. | Methods for treating ocular Demodex using lotilaner formulations |
US11752137B2 (en) | 2017-12-15 | 2023-09-12 | Tarsus Pharmaceuticals, Inc. | Ophthalmic compositions for treating ocular Demodex using lotilaner formulations |
WO2021035086A1 (en) * | 2019-08-21 | 2021-02-25 | Timber Pharmaceuticals, Inc. | Solvent delivery system for topical delivery of active agents |
KR20220052473A (en) | 2020-10-21 | 2022-04-28 | 순천향대학교 산학협력단 | MicroRNA-31-5p for diagnosing rosacea and use thereof |
KR20220052474A (en) | 2020-10-21 | 2022-04-28 | 순천향대학교 산학협력단 | MicroRNA-21-3p for diagnosing rosacea and use thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11033565B2 (en) | Topical application of ivermectin for the treatment of dermatological conditions/afflictions | |
CA2522579C (en) | Topical formulation of ivermectin for the treatment of dermatological conditions | |
US20160303152A1 (en) | Topical Composition of Ivermectin | |
US10744112B2 (en) | Composition comprising avermectin compounds without solvents and propenetrating agents of avermectin compounds | |
US10695315B2 (en) | Composition comprising avermectin compounds without gelling agents | |
US20160303151A1 (en) | Topical Composition of Ivermectin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004728811 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004231323 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 200507346 Country of ref document: ZA |
|
ENP | Entry into the national phase |
Ref document number: 2004231323 Country of ref document: AU Date of ref document: 20040422 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004231323 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020057019402 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006505405 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2522579 Country of ref document: CA Ref document number: PA/a/2005/011208 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 20048109954 Country of ref document: CN Ref document number: 11255910 Country of ref document: US |
|
WWE | Wipo information: entry into national phase |
Ref document number: 5399/DELNP/2005 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2005136438 Country of ref document: RU |
|
WWP | Wipo information: published in national office |
Ref document number: 1020057019402 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2004728811 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 11255910 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: PI0410503 Country of ref document: BR |